Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD1722 salt tablet
AZD1722 salt · 1 trial · 1 indication
Sodium and phosphorus content in stool collected over 24-hour intervals
| Arm | Type | Description |
|---|---|---|
| Treatment A AZD1722 salt tablet (fasted) | EXPERIMENTAL | Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner |
| Treatment B AZD1722 salt tablet (fed) | EXPERIMENTAL | Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner |
| Treatment C AZD1722 salt tablet (fasted) | EXPERIMENTAL | Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption |
| Treat D AZD1722 free-base tablet (fast) | EXPERIMENTAL | Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner |
| Treat E AZD1722 free-base+Omeprazole | EXPERIMENTAL | Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722 |
| Name | Type | Description |
|---|---|---|
| AZD1722 salt tablet | DRUG | AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3). |
| AZD1722 free base tablet | DRUG | AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2). |
| AZD1722 free base tablet + Omeprazole | DRUG | AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722 |
Inclusion Criteria: 1. Healthy male and female volunteers aged 18 to 65 years 2. Females of childbearing potential had to have a negative pregnancy test and females of childbearing potential included in the study had to use 2 effective methods of avoiding pregnancy, females of nonchildbearing poten...
AZD1722 salt is an investigational small molecule developed by Ardelyx, Inc. (ticker ARDX). It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific therapeutic indication for AZD1722 salt has not been disclosed.
AZD1722 salt is being developed by Ardelyx, Inc., which trades on the Nasdaq under the ticker ARDX. Ardelyx is the sponsor of the clinical program for AZD1722 salt.
AZD1722 salt is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
AZD1722 salt has been evaluated in one completed Phase 1 trial, NCT02226783, titled D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects. The trial enrolled 37 healthy volunteers in the United States and was randomized and controlled.
Yes, AZD1722 salt tablet is another name for AZD1722 salt. The completed Phase 1 trial, NCT02226783, used the tablet formulation of AZD1722 salt in healthy subjects.